Targeted therapy: resistance and re-sensitization.
10.1186/s40880-015-0047-1
- Author:
Dao-Hong CHEN
1
;
Xiao-Shi ZHANG
2
;
Author Information
1. Biomedical Research Institute, Yiling Pharmaceutical Company, Beijing, 102600, P. R. China. daohong@hotmail.com.
2. Biotherapy Center, Sun Yat-sen University Cancer Center
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Drug Resistance, Neoplasm;
Humans;
Neoplasms;
Signal Transduction
- From:Chinese Journal of Cancer
2015;34(11):496-501
- CountryChina
- Language:English
-
Abstract:
The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncology and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a number of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical efficacy and minimized adverse effects compared with traditional treatments, the challenging drug-resistant issue has also emerged to limit their benefits to cancer patients. In this regard, we aim to improve targeted therapy by presenting a systematic framework regarding the drug resistance mechanisms and alternative approaches to re-sensitize cancer cells/tissues therapeutically.
